Hepatitis Central

Determinants of Outcome of Compensated Hepatitis C Virus-Related Cirrhosis

References

1. Feray C, Gigou M, Samuel D, Paradis V, David MF, Lemonnier C, et al. The course of hepatitis C virus infection after liver transplantation. HEPATOLOGY 1994; 20: 1137-1143[Abstract].

2. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated Non-A, Non-B hepatitis. N Engl J Med 1992; 327: 1906-1911[Medline].

3. Koretz RL, Abey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993; 119: 110-115[Medline].

4. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. HEPATOLOGY 1991; 14: 969-74[Abstract].

5. Hopf U, Küther D, Stemerowicz R, Stemerowicz R, Lobeck H, Lüdtke-Handjery A, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10: 69-76[Medline].

6. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-281[Medline].

7. Tong JM, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466[Medline].

8. Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tomasini M, et al. Hepatocellular carcinoma in italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680[Medline].

9. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. HEPATOLOGY 1993; 18: 47-53[Abstract].

10. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801[Medline].

11. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-years prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21: 1029-1034[Medline].

12. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C, the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-168[Medline].

13. Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A, et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994; 21: 468-473[Medline].

14. Pozzato G, Kaneko S, Morreti M, Saveria Croce L, Franzin F, Unoura M, et al. Different genotypes of hepatitis C virus are associated with different severity of liver disease. J Med Virol 1994; 43: 291-296[Medline].

15. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39: 234-239[Medline].

16. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055[Medline].

17. Mazzela G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-147[Medline].

18. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102[Medline].

19. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994; 19: 1321-1324[Medline].

20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431-435[Abstract].

21. Kaplan EL, Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-481.

22. Cox DR. Regression models and lifes tables. J R Stat Soc B 1972; 34: 248-275.

23. Serfaty L, Chazouillères O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chrétien Y, et al. Risk factors for liver cirrhosis in patients with chronic HCV infection: results of a case control study. HEPATOLOGY 1997; 26: 776-779[Abstract].

24. Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono O, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. HEPATOLOGY 1994; 19: 820-828[Abstract].

25. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-1717[Abstract].

26. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17[Medline].

27. Fattovich G, Giustina G, Degos F, Tremolada F, Diaodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472[Abstract].

28. Castilla A, Prieto J, Fausto N. Transforming growth factors b 1 and alfa in chronic liver disease. Effects of interferon therapy. N Engl J Med 1991; 324: 933-940[Medline].

29. Manabe M, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon-alfa 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evolution. HEPATOLOGY 1993; 18: 1344-1349[Abstract].

30. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoïd alfa-interferon in chronic hepatitis C. Effect on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17: 390-396[Medline].

31. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploïd fibroblast collagen synthesis by interferon. J Clin Invest 1984; 74: 1112-1116[Medline].

32. Mavier P, Préaux AM, Charlotte F, Dhumeaux D, Rosenbaum J. Effects of alpha- and gamma-interferons on the growth and collagen synthesis of human hepatic myofibroblastic Ito cells [Abstract]. HEPATOLOGY 1992; 16: 185A.

33. Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma. HEPATOLOGY 1993; 18: 315-319[Abstract].

34. Baron S, Tyring SK, Fleischmann WR, Coppenhauer DH, Niesel DW, Klimpel GR. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-1383[Medline].

35. Sing RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferon alfa and down-regulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci U S A 1995; 92: 4562-4566[Medline].

36. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life- threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456[Medline].

Return To Article

Copyright © 1998 by the American Association for the Study of Liver Diseases.